Form 8-K - Current report:
SEC Accession No. 0000950170-24-056871
Filing Date
2024-05-09
Accepted
2024-05-09 16:04:53
Documents
12
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20240509.htm   iXBRL 8-K 40135
2 EX-99.1 kzr-ex99_1.htm EX-99.1 72335
  Complete submission text file 0000950170-24-056871.txt   231021

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240509.xsd EX-101.SCH 23930
15 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240509_htm.xml XML 4536
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 24930385
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)